NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 16, 2002--Acacia Research Corporation announced today that its two new classes of common stock, Acacia Research -- CombiMatrix (Nasdaq:CBMX - News) and Acacia Research -- Acacia Technologies (Nasdaq:ACTG - News), have commenced trading on the Nasdaq stock market. The two new classes of common stock were created as a result of Acacia's recapitalization that was recently approved by the company's stockholders.
The two new classes of stock replace Acacia's common stock that formerly traded on the Nasdaq stock market under the symbol ACRI. Acacia Research -- CombiMatrix stock is intended to reflect the performance of its subsidiary, CombiMatrix Corporation, and Acacia Research -- Acacia Technologies stock is intended to reflect the performance of Acacia Research's media technology businesses. The Acacia Research -- CombiMatrix stock and the Acacia Research -- Acacia Technologies stock are both classes of common stock of Acacia Research and are not stock issued by the respective groups.
About Acacia Research Corporation
Acacia Research Corporation comprises two operating groups. The Acacia Technologies group consists of our media technology business that licenses its V-chip technology to television manufacturers, and owns pioneering Digital Media Transmission ("DMT") technology. DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents.
The CombiMatrix group, consisting of our wholly-owned subsidiary CombiMatrix Corporation, is developing a platform technology that has a wide range of applications, from DNA synthesis/diagnostics to immunochemical detection. The platform allows the company to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The company is designing its products principally to be responsive to the needs of pharmaceutical, biotechnology, and academic researchers in analyzing raw genomic data in the discovery and development of pharmaceutical products. Information about Acacia Research Corporation is available at www.acaciaresearch.com. Information about CombiMatrix Corporation is available at www.combimatrix.com. |
